Adding the PCSK9 inhibitor led to greater absolute reductions in CVD risk than in younger patients, with no signs of safety ...

Uncertainty regarding the effectiveness and safety of intensive low-density lipoprotein cholesterol (LDL-C) reduction in ...

Goldman Sachs initiated coverage on Silence Therapeutics (NASDAQ:SLN), currently trading at $4.92 with a market cap of $232.3 million, with a Sell rating and a price target of $6.00. According to ...

Atherosclerotic Cardiovascular Disease (ASCVD), including conditions such as heart attacks and strokes, remains a leading ...

A research team revealed that insulin-like growth factor-binding protein 6 (IGFBP6) serves as a potential therapeutic target ...

A research team led by Prof. WENG Jianping from the University of Science and Technology of China (USTC) of the Chinese Academy of Sciences (CAS) revealed that insulin-like growth factor-binding ...

Individuals with cutaneous lupus erythematosus have an increased ASCVD risk when compared with those without cutaneous lupus erythematosus.

LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company today announced the U.S. Food and Drug Administration (FDA) has ac ...

Anderson, M.D., from the University of Pittsburgh, characterized national trends in preventive aspirin use (primary and secondary prevention) among populations at low and high ASCVD risk and with ...

View Full Profile. Learn about our Editorial Policies. The genetic predisposition to atherosclerotic cardiovascular disease (ASCVD) constitutes half of the known risk. Specific genetic variations, ...

Atherosclerosis cardiovascular disease (ASCVD)-related mortality is higher in patients with lupus nephritis (LN) compared ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...